Clinical Trial Update: A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) [Phase 1]

View source ↗

Summary

Phase 1 study of MK-5720 in participants with schizophrenia completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-5720

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2025-03-04